Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).

Stage IIIA Fallopian Tube Cancer

Stage IIIA Ovarian Cancer

Stage IIIA Primary Peritoneal Cancer

Stage IIIB Fallopian Tube Cancer

Stage IIIB Ovarian Cancer

Stage IIIB Primary Peritoneal Cancer

Stage IIIC Fallopian Tube Cancer

Stage IIIC Ovarian Cancer

Stage IIIC Primary Peritoneal Cancer

Stage IV Fallopian Tube Cancer

Stage IV Ovarian Cancer

Stage IV Primary Peritoneal Cancer

(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)

Positron Emission Tomography

Laboratory Biomarker Analysis

PET Imaging of Ovarian Carcinoma With 18F-FSPG

All imaging data (SUV) will be correlated to definitive, ex vivo diagnostic pathology and immunoreactivity (xC-, CD44), which will be carried out for every patient with resected tissue. and, when IHC scoring will be in terms of strength of immunostaining (scored on an ordinal scale of 0 3). This treatment of lesion-based sensitivity and specificity has not been previously described in the ovarian cancer literature.

We will test that lesion 18F-FSPG PET SUV's are significantly greater than background (normal liver tissue) by tissue assessment of number of lesions noted in each arm and after treatment.

Marta Crispens, MD

Professor

Vanderbilt-Ingram Cancer Center

National Cancer Institute (NCI)

Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.

Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
18F-FSPG: Administered intravenously (IV)
18F-FDG: Administered intravenously (IV)

18F-FSPG and 18F-FDG Intragroup Comparision

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Standard Uptake Values (SUVs) for the radiotracers labels 18F-FSPG and 18F-FDG were assessed in tumor tissues of study participants, before (baseline), and after therapeutic treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported as the difference of means from baseline to post-treatment (a number without dispersion), for all lesions for which an SUVmax value was assessed. A negative result indicates less uptake of radiotracer suggesting a small volume of tumor.

Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment

Safety and tolerability of 18F-FSPG and 18F-FDG were assessed as treatment-related adverse events, and reported as the number of events related to each treatment, without dispersion.

Number of Treatment-Related Adverse Events

Lesion size in centimeters (cm) were assessed in 2 dimensions from the computed tomography (CT) component of PET/CT and the area in cm2 calculated for lesion locations at baseline and after treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported the difference in area in cm² for each lesion (a number without dispersion).

Participants sequentially receive radioimaging agent 18F-FSPG IV followed by PET/CT scan with 60 minutes.
18F-FSPG: Administered intravenously (IV)

Difference in Lesion Size as Detected by 18F-FSPG

Participants sequentially receive radioimaging agent 18F-FDG IV followed by PET/CT scan with 60 minutes.
18F-FDG: Administered intravenously (IV)

Difference in Lesion Size as Detected by 18F-FDG

Change From Baseline in Lesion Size Post-treatment, by 18F-FSPG or 18F-FDGs

Overall Study

Andrei H. Iagaru

B-Cell Neoplasm

Estrogen Receptor Negative

HER2/Neu Negative

Metastatic Renal Cell Cancer

Progesterone Receptor Negative

Stage III Mesothelioma

Stage III Renal Cell Cancer

Stage IIIA Breast Cancer

Stage IIIA Non-Small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer

Stage IIIC Breast Cancer

Stage IV Breast Cancer

Stage IV Mesothelioma

Stage IV Non-Small Cell Lung Cancer

Stage IV Renal Cell Cancer

Triple-Negative Breast Carcinoma

18F-FSPG

18F-FDG

Stanford University Medical Center

18F-FSPG PET/CT for Cancer Patients on Therapy

An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy

l glutamic acid/xərçəng xəstəliyi

PET Imaging of Ovarian Carcinoma With 18F-FSPG

18F-FSPG PET/CT for Cancer Patients on Therapy

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası